x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Decera Clinical Education Oncology Podcast

Decera Clinical Education

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

education courses

All Episodes

00:10:33

Evolving Role of BTK Inhibitors in CLL: Experts...

Decera Clinical Education Oncology Podcast ·

2022/11/09

In this episode, Farrukh T. Awan, MD, and Nicole Lamanna, MD, answer questions from an audience of healthcare professionals on topics related to the use of BTK inhibitors for the management of chronic lymphocytic leukemia (CLL). The topics covered include:Whether it is justifiable to use chlorambucil plus obinutuzumab as a control arm in a registrational trial todayRelevance of overall response rate vs progression-free survival for BTK inhibitor therapyApproval of ibrutinib/venetoclax combination

en

00:21:46

New Evidence With BTK Inhibitor Therapy in CLL and...

Decera Clinical Education Oncology Podcast ·

2022/10/28

In this episode, Christopher R. Flowers, MD, MS, and Kami Maddocks, MD, discuss their choices of recent important trials presented at the Society of Hematologic Oncology 2022 Annual Meeting evaluating the use of BTK inhibitors in chronic lymphocytic leukemia and mantle cell lymphoma. The discussion includes analyses of:GLOW: phase III randomized trial of ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab for older or unfit patients with previously untreated chronic lymphocytic

en

01:18:59

Relapsed/Refractory Myeloma: Navigating the Complex...

Decera Clinical Education Oncology Podcast ·

2022/10/24

In this podcast episode from Clinical Care Options, Paul G. Richardson, MD; Natalie S. Callander, MD; and Noopur Raje, MD, answer questions from a live webinar on therapeutic options currently available for patients with relapsed/refractory multiple myeloma. The topics covered include:How to sequence currently available therapies after relapseChallenges with using BCMA-targeted agents in clinical practiceExperts’ thoughts on the potential approval of bispecific agentsPresenters include:Paul G

en

00:15:21

Expert Thoughts on Key Trials of Interest for Ovarian...

Decera Clinical Education Oncology Podcast ·

2022/10/24

In this episode,Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2022 Annual Global Meeting for ovarian and cervical cancers including:Post-hoc analyses from SOLO-3: olaparib vs physician’s choice chemotherapy in germline BRCA mutant platinum-sensitive recurrent ovarian cancerPhase III CALLA trial: durvalumab combined with and following chemoradiation for locally-advanced cervical cancerPhase III ARIEL3: final OS for

en

00:19:39

Expert Insights on Key Updates From the 2022 ESMO...

Decera Clinical Education Oncology Podcast ·

2022/10/04

In this episode, Domenica Lorusso, MD, PhD, and Alexandra Leary, MD, PhD, provide their expert insights on key updates presented for ovarian cancer trials including:Phase III GOG-3004/SOLO-1: OS results after 7 years of follow-up for patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib vs placeboPhase III ENGOT-ov25/PAOLA-1: final OS results from the trial of maintenance therapy with olaparib with bevacizumab vs bevacizumab alone in women with newly diagnosed advanced

en

00:29:48

Managing EGFR-Mutated Non-Small-Cell Lung Cancer in...

Decera Clinical Education Oncology Podcast ·

2022/09/28

In this episode, Ryan D. Gentzler, MD, MS, and Jonathan Riess, MD, MS, answer audience questions on managing EGFR-mutated non-small-cell lung cancer (NSCLC) from a live meeting series. The episode includes expert insights on:• Identifying patients who may benefit the most from adjuvant osimertinib • Testing for EGFR mutations in early-stage NSCLC• Critical importance of getting molecular test results before starting immunotherapy• Monitoring cardiac toxicity in patients receiving osimertinib• Key

en

00:28:34

New Evidence With BTK Inhibitor Therapy in CLL and...

Decera Clinical Education Oncology Podcast ·

2022/08/30

In this episode, Julie M. Vose, MD, MBA, and Matthew S. Davids, MD, MMSc, discuss their choices of recent important trials presented at the Pan Pacific Lymphoma Conference 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: BRUIN (CLL/small lymphocytic lymphoma [SLL]): phase I/II study of pirtobrutinib for previously treated CLL (including previous BTK inhibitor)SEQUOIA: phase III study evaluating cohort

en

00:26:12

Experts Discuss Challenges in Advanced Hepatocellular...

Decera Clinical Education Oncology Podcast ·

2022/08/22

In this podcast episode from Clinical Care Options (CCO), Heinz-Josef Klumpen, MD, PhD, and Chris Verslype, MD, PhD, discuss challenges in selecting and sequencing therapy for patients with advanced hepatocellular carcinoma. Topics include:Factors to consider before selecting frontline immunotherapyRole of TKIs in the frontlineImpact of Child-Pugh status on the efficacy of immunotherapy/VEGF inhibitor combination therapyReal-world evidence on frontline immunotherapy/VEGF combination therapyFactors

en

00:39:32

HER2-Positive Breast Cancer: Current Approaches for...

Decera Clinical Education Oncology Podcast ·

2022/07/28

In this episode, Erika P. Hamilton, MD, and Komal Jhaveri, MD, discuss their approaches to and key studies for current management of patients with HER2-positive breast cancer. The discussion includes: Optimizing systemic therapy for patients with HER2-positive early breast cancer based on disease characteristics and riskSequencing available therapies for patients with HER2-positive metastatic disease, including new data on first- and second-line therapy and how to manage patients with central

en

00:26:22

New Evidence With BTK Inhibitor Therapy in CLL and...

Decera Clinical Education Oncology Podcast ·

2022/07/21

In this episode, Othman Al-Sawaf, MD, and Lydia Scarfò, MD, discuss key trials presented at EHA 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion includes analyses of: GAIA/CLL13: phase III trial of time-limited venetoclax + obinutuzumab ± ibrutinib vs chemoimmunotherapy as first-line therapy for CLLFLAIR: randomized, adaptive-design phase III trial with data reported from ibrutinib + venetoclax and ibrutinib arm; includes

en

00:32:16

New Evidence With BTK Inhibitor Therapy in CLL and...

Decera Clinical Education Oncology Podcast ·

2022/07/06

In this episode, Brad S. Kahl, MD, and Anthony Mato, MD, MSCE, discuss their choices of 3 recent important trials presented at ASCO 2022 evaluating the use of BTK inhibitors in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The discussion will include analyses of: The SHINE trial evaluating the addition of ibrutinib to bendamustine/rituximab followed by rituximab maintenance in the first-line setting for older patients with MCL3-year follow-up analysis from the CAPTIVATE

en

00:38:27

Expert Insights on New Data From ASCO 2022 Informing...

Decera Clinical Education Oncology Podcast ·

2022/06/30

In this episode, Jubilee Brown, MD, and Elisabeth Diver, MD, provide expert insights on new data presented at ASCO 2022 for ovarian, endometrial, and cervical cancers regarding:Subgroup analyses from KEYNOTE-826 evaluating pembrolizumab in combination with chemotherapy with or without bevacizumab in persistent, recurrent, or metastatic cervical cancerPreliminary subgroup analyses from phase III ENGOT-EN5/GOG-3055 SIENDO trial of selinexor vs placebo maintenance in recurrent endometrial cancerUpdated

en

00:46:39

Expert Insight on Key Data From SGO 2022 Informing...

Decera Clinical Education Oncology Podcast ·

2022/05/19

In this episode, David Scott Miller, MD, FACOG, FACS, and Angeles Alvarez Secord, MD, MHSc, provide expert insights on key data presented at SGO 2022 for ovarian, endometrial, and cervical cancers regarding:Results from the prospective phase III PRIME study of an individualized dose for niraparib vs placebo maintenance in newly diagnosed advanced ovarian cancerFinal OS analysis from phase III SOLO-3 evaluating olaparib vs physician’s choice of single-agent nonplatinum chemotherapy in gBRCAm

en

00:19:44

Call to Action and Reflection: Inclusive,...

Decera Clinical Education Oncology Podcast ·

2022/05/13

In this episode for all healthcare professionals and any patient-facing clinical staff, Nelson F. Sanchez, MD, shares key insights on the need for equitable, compassionate healthcare for transgender individuals, along with practical guidance based on his clinical experience caring for these patients. Topics include:Communication and physical exam skillsSpecific clinical care needs of transgender individuals related to transitionCreating an inclusive and welcoming environment for transgender patients

en

00:16:43

Inclusive Healthcare for Transgender Individuals:...

Decera Clinical Education Oncology Podcast ·

2022/05/02

In this episode, Pharmacist Olivia Buckoski shares her experience undergoing medical and social transition and offers advice from the perspective of both a transgender person and healthcare professional on caring for transgender individuals. Topics include:Importance of educating entire care team about needs of transgender individuals, starting with the waiting roomSpecific advice for the exam roomPharmacy and adherence considerations with hormone therapyExamples of uninformed care

en

00:22:02

Anti-TIGIT Therapy: Overview of Current Clinical...

Decera Clinical Education Oncology Podcast ·

2022/04/15

In this episode, Jyoti D. Patel, MD, and Ani Balmanoukian, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising results in PD-L1-positive NSCLC. The episode includes a review of phase II data on the use of tiragolumab plus atezolizumab in NSCLC, the use of PD-L1 as a marker of response, the potential role of anti-TIGIT therapies in solid tumors, and ongoing trials in lung cancer including SKYSCRAPER-01, SKYSCRAPER-02, SKYSCRAPER-03,

en

00:20:40

Targeting TIGIT: Understanding New Approaches for...

Decera Clinical Education Oncology Podcast ·

2022/04/07

In this episode, Jyoti D. Patel, MD, and Diwakar Davar, MD, discuss several studies investigating agents targeting TIGIT, an emerging immune checkpoint target with promising early-phase clinical trial results. The episode includes a comprehensive explanation of TIGIT, how the TIGIT pathway functions, and the potential role of TIGIT inhibition for the treatment of cancer, including analyses from ongoing clinical trials such as CITYSCAPE, PACIFIC-8, ARC-7, and SKYSCRAPER-01.Presenters:Jyoti D. Patel,

en

00:21:24

Evolving Treatment Landscape With Regorafenib and...

Decera Clinical Education Oncology Podcast ·

2022/04/06

In this episode, Nilofer S. Azad, MD, and Kanwal Raghav, MD, discuss current and emerging uses of regorafenib and TAS-102 in later-line treatment of patients with mCRC, with topics including:Current use of regorafenib and TAS-102 monotherapyCombination therapy with regorafenib and PD-1 inhibitorsAdding bevacizumab to TAS-102Presenters:Nilofer S. Azad, MD Professor, Oncology Sidney Kimmel Comprehensive Cancer Center Johns Hopkins UniversityBaltimore, Maryland Kanwal Raghav, MDAssociate Professor,

en

00:28:04

Expert Answers to Key Questions on Current and...

Decera Clinical Education Oncology Podcast ·

2022/03/31

In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?What is the optimal therapy for a patient with del(17p) CLL?When should an

en

00:34:01

Expert Insights on Optimal Current Management of...

Decera Clinical Education Oncology Podcast ·

2022/03/21

In this episode, Lipika Goyal, MD, leads an engaging discussion with Christine Chio, PharmD, BCOP, and Caroline Kuhlman, NP, on current treatment of patients with cholangiocarcinoma. Topics include:Initial diagnosisBiomarker testing to guide treatment with immunotherapies and targeted agentsAdverse event managementStrategies for counseling patientsPresenters:Christine Chio, PharmD, BCOPClinical Ambulatory GI Oncology PharmacistDepartment of PharmacyMassachusetts General HospitalBoston,

en

237 results

Similar Podcasts

Science Talk

Albert Einstein College of Medicine

五分钟心理学

柠檬心理

Daily Facts

Amalia Dupray and Montgomery Jones.

Les dents et dodo

BFMTV

Veterinary Clinical Podcasts

The Royal Veterinary College